Trademarkia Logo

Canada

C$
ZYFARSA
REGISTERED

on 12 Feb 2024

Last Applicant/ Owned by

GLAXO GROUP LIMITED

GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY

GB

Serial Number

2092717 filed on 8th Jan 2021

Registration Number

TMA1221136 registered on 12th Feb 2024

Registration expiry Date

8th Jan 2031

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

ZYFARSA

Trademark usage description

pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficien Read More

Classification Information


Class [005]
Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus (HPV), respiratory syncytial virus (RSV), hepatitis, herpes genitals, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely, disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone disorders, androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders, namely acidifiers to increase levels of gastric acid to decrease stomach pH for human purposes; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders namely amenorrhoea, dysmenorrhoeal and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparation, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids, Leiomyoma, endourological disorders and for the removal of renal calculi and the treatment of nephrolithiasis and urolithiasis, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medication; vaccines for human use.


Classification kind code

11

Mark Details


Serial Number

2092717

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 48
on 12th Sept 2022
Agent Changed
Submitted for opposition 22
on 15th Jul 2022
Search Recorded
Submitted for opposition 20
on 15th Jul 2022
Examiner's First Report
Submitted for opposition 223
on 15th Jul 2022
Total Provisional Refusal
Submitted for opposition 256
on 18th Jan 2022
Notification of Possible Opposition Sent
Submitted for opposition 257
on 18th Mar 2021
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 17th Mar 2021
Formalized
Submitted for opposition 1
on 17th Mar 2021
Created
Submitted for opposition 228
on 8th Jan 2021
International Registration
Submitted for opposition 30
on 8th Jan 2021
Filed